BUZZ-Valeant: The Street View

Thu Oct 22, 2015 7:41am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

** Valeant Pharmaceuticals plunge overnight following Citron's report cost investor billions but analysts at bulge-bracket banks sitting tight on recommendations

** UBS, BAML both sticking with "buy" ratings on the stock while Morgan Stanley and Deutsche Bank keeping their "equalweight" and "hold" ratings respectively

** As of Wednesday's close only 1 analyst had a "sell" rating on the stock, according to StarMine

** BMO Capital Markets cut its rating on Valeant to "market perform" from "outperform" early Thursday

** Valeant long a bane to short sellers

** Shares are off 3 pct in US premarket trading. Almost $10 bln worth of Valeant shares traded on Wednesday across US venues with stock falling nearly 40 pct at its day's low

A summary of analyst views so far: